Forte Biosciences Files 2024 Annual Report

Ticker: FBRX · Form: 10-K · Filed: Mar 28, 2025 · CIK: 1419041

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

Related Tickers: FBRX

TL;DR

Forte Bio (FBRX) dropped its 2024 10-K. Check financials.

AI Summary

Forte Biosciences, Inc. filed its 2024 annual report on March 28, 2025, detailing its financial performance and business operations. The company, formerly known as Tocagen Inc., is focused on pharmaceutical preparations. Key financial data and operational details for the fiscal year ending December 31, 2024, are presented in this 10-K filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Forte Biosciences' financial health and strategic direction for the past fiscal year, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Forte Biosciences faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is Forte Biosciences' primary business focus?

Forte Biosciences, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].

When did Forte Biosciences change its name from Tocagen Inc.?

The date of the name change from Tocagen Inc. to Forte Biosciences, Inc. was November 20, 2007.

What is the business address of Forte Biosciences?

The business address for Forte Biosciences, Inc. is 3060 PEGASUS PARK DRIVE, BUILDING 6, DALLAS, TX 75247.

What is the SEC file number for Forte Biosciences?

The SEC file number for Forte Biosciences, Inc. is 001-38052.

What is the fiscal year end for Forte Biosciences?

The fiscal year end for Forte Biosciences, Inc. is December 31.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 28, 2025 regarding Forte Biosciences, Inc. (FBRX).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing